CEWG January 09 Full Report - National Institute on Drug Abuse

More documents

Recommendations

Info

Section IV. Across <strong>CEWG</strong> Areas: Treatment Admissions, Forensic Laboratory Analysis Data, and Average Drug Price and Purity Data Club Drugs (MDMA, GHB/GBL, LSD, Ketamine) Treatment Admission Data on Club Drugs The club drugs reported on in this section include MDMA (methylenedioxymethamphetamine, or ecstasy), GHB (gamma hydroxybutyrate), GBL (gamma butyrolactone), LSD (lysergic acid diethylamide), and ketamine. Admissions for primary treatment of club drugs or MDMA are not captured in all treatment data systems, but they appear low in those areas that do report on these drugs. Forensic Laboratory Data on Club Drugs MDMA. MDMA was the club drug most frequently reported among NFLIS data in the 22 <strong>CEWG</strong> areas depicted in table 12. As shown, MDMA equaled or exceeded 2 percent of all drug items in 11 areas. These include Atlanta and San Francisco, which had the highest percentage (3.8 percent each), followed by Detroit (3.7 percent), Minneapolis/St. Paul (3.6 percent), and Seattle (3.2 percent). Others in this group were St. Louis, Los Angeles, Honolulu, Denver, Washington, DC, and San Diego (table 12). As shown in section II, table 1, MDMA was the third most frequently identified drug item in Atlanta, and it ranked fourth in Chicago, Minneapolis/St. Paul, and Honolulu in the first half of 2008. GHB. GHB items were reported among the forensic laboratory data in 10 <strong>CEWG</strong> areas: Boston, Chicago, Los Angeles, New York City, San Diego, San Francisco, Seattle, St. Louis, Texas, and Washington, DC. These items accounted for much less than 1 percent of all items in all reporting areas. GHB was not among the top 10 drugs reported from any <strong>CEWG</strong> area (table 13 and section II, table 1). LSD. LSD was reported in the forensic laboratory data among drug items identified for 17 <strong>CEWG</strong> metropolitan areas. None, however, had 30 or more cases. LSD was not among the top 10 drugs reported for any <strong>CEWG</strong> reporting area, and no LSD items were reported from Albuquerque, Detroit, Honolulu, Phoenix, and Washington, DC (table 13 and section II, table 1). Ketamine. Ketamine items were reported among drug items identified from all except 5 of 22 <strong>CEWG</strong> areas during the first half of 2008. While ketamine represented less than 1 percent of total drug items identified in any reporting area, four areas reported 30 cases or more: Texas, New York City, Los Angeles, and Atlanta (table 13). Ketamine did not figure among the top 10 most frequently identified drug items in any <strong>CEWG</strong> area (section II, table 1). Proceedings of the Community Epidemiology Work Group, <strong>January</strong> 20<strong>09</strong> 95
EpidEmiologic TrEnds in drug AbusE: HigHligHTs And ExEcuTivE summAry Phencyclidine (PCP) Forensic Laboratory Data on PCP No PCP items were documented among the forensic laboratory data on drug items identified in eight <strong>CEWG</strong> areas (Albuquerque, Atlanta, Cincinnati, Denver, Detroit, Honolulu, Miami, and Minneapolis/St. Paul), and fewer than 30 such items were identified in seven areas (Baltimore City, Boston, Phoenix, San Diego, San Francisco, Seattle, and St. Louis). The areas reporting 30 or more PCP items were Chicago, Los Angeles, New York City, Philadelphia, Maryland, Texas, and Washington, DC. As a percentage of all identified items, PCP items were highest in Washington, DC, at 5.6 percent, followed by Philadelphia, at 2.7 percent, and New York City, at 1.5 percent (table 13; appendix table 2). Table 12. Number of MDMA Items Identified and MDMA Items as a Percentage of Total Items Identified by Forensic Laboratories in 22 <strong>CEWG</strong> Areas 1 : 1H 2008 2 <strong>CEWG</strong> Area MDMA Items Total Items Percentage of Total Items Albuquerque 6 733 * Atlanta 257 6,779 3.8 Baltimore City 70 28,288 * Boston 58 14,921 * Chicago 522 40,400 1.3 Cincinnati 58 7,011 * Denver 91 4,252 2.1 Detroit 131 3,527 3.7 Honolulu 25 1,143 2.2 Los Angeles 683 29,567 2.3 Maryland 121 33,219 * Miami 142 16,015 * Minneapolis/St. Paul 90 2,502 3.6 New York City 135 27,064 * Philadelphia 37 16,057 * Phoenix 36 3,372 1.1 San Diego 207 10,234 2.0 San Francisco 455 11,925 3.8 Seattle 51 1,573 3.2 St. Louis 257 9,605 2.7 Texas 663 47,868 1.4 Washington, DC 48 2,3<strong>09</strong> 2.1 1 Only percentages of 1.0 or higher are reported in this table; percentages of less than 1.0 are indicated by the symbol *. 2 Data are for the first half of 2008: <strong>January</strong>–June 2008. SOURCE: All data were received from NFLIS, DEA, <strong>January</strong> 4, 20<strong>09</strong> (see appendix table 2); data are subject to change and may differ according to the date on which they were queried 96 Proceedings of the Community Epidemiology Work Group, <strong>January</strong> 20<strong>09</strong>
Page 1 and 2:
EpidEmiologic TrEnds in drug AbusE
Page 3 and 4:
EpidEmiologic TrEnds in drug AbusE:
Page 5 and 6:
Page 7 and 8:
Foreword Foreword This Executive Su
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
58.9 17.5 1.8 1.5 EpidEmiologic TrE
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52: EpidEmiologic TrEnds in drug AbusE:
Page 101: EpidEmiologic TrEnds in drug AbusE:
Page 115 and 116: Participant List Participant List <
Page 117 and 118: Participant List Daniel P. Dooley S
Page 119 and 120: Participant List John A. Newmeyer,
Page 121: NIH Publication No. 09</str
show all

CEWG January 09 Full Report - National Institute on Drug Abuse

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?